Belite Bio, Inc. (BLTE) announced that the U.S. FDA has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease based on the previously reported interim data from the ongoing Phase 3 DRAGON trial. The designation is based on the phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant's efficacy and favorable safety profile. There are currently no approved treatments for Stargardt disease.
Hendrik Scholl, Chief Medical Officer of Belite Bio, said: "We look forward to continuing to evaluate Tinlarebants safety and efficacy as the DRAGON trial progresses."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.